ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2884

Prevalence Of Structural Lesions Seen On MRI-Spine In Patients With (Possible) Axial Spondyloarthritis (axSpA) Included In The SPACE-Cohort

Manouk de Hooge1, Rosaline van den Berg2, Victoria Navarro-Compán2, Monique Reijnierse3, Floris van Gaalen2, Karen Fagerli4, Maureen C. Turina5, Maikel van Oosterhout6, Roberta Ramonda7, Tom Huizinga2 and Désirée van der Heijde8, 1Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Radiology, Leiden University Medical Center, Leiden, Netherlands, 4Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 5Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 6Rheumatology, GHZ Hospital, Gouda, Netherlands, 7Rheumatology Unit, University of Padova, Padova, Italy, 8Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: MRI and spondylarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Imaging in Axial Spondylarthropathies: Challenges, Advances

Session Type: Abstract Submissions (ACR)

Background/Purpose: Little is known about the prevalence of structural lesions (erosions, syndesmophytes, fatty lesions) on MRI of the spine (MRI-spine) in patients with chronic back pain. Therefore the purpose of our study was to investigate the prevalence of structural lesions on MRI-spine in patients with chronic back pain.

Methods: Patients with back pain (≥3 months, ≤2 years, onset <45 years) recruited from 5 participating centres in Europe were included in the SPondyloArthritis Caught Early (SPACE)-cohort. Patients underwent MRI-spine scored independently by 3 blinded, well-calibrated readers for presence of erosions, fatty lesions and (bridging) syndesmophytes on T1-weighted images (STIR images viewed simultaneously). Fatty lesions suggestive of spondylitis were scored when visible on ≥2 consecutive slices. For erosions and syndesmophytes, suggestive of spondylitis, the presence on ≥1 slice was sufficient.  Agreement of 2/3 readers was used. The prevalence of structural lesions was calculated based on several cut-offs.

Results: All patients with complete MRI-spine data were included for analysis (n=306). All patients were grouped according to the ASAS axSpA criteria; imaging arm (fulfilling the modified New York criteria (mNY+) and not fulfilling the modified New York criteria (mNY-)) and clinical arm, possible SpA (patients not fulfilling the ASAS axSpA criteria but with 1 SpA feature with a LR+ of ≥6 or 2 SpA features with a LR+ <6) and no-axSpA. Prevalence of fatty lesions was the highest of all structural lesions in the spine in all subgroups. With a cut-off of ≥3 fatty lesions, the ‘false-positive’ rate in the no-axSpA group was low (6.5%) with still a considerable prevalence in the imaging and radiographic axSpA groups. The prevalence of erosions and syndesmophytes was generally low (see the table).

Conclusion: The prevalence of fatty lesions on MRI-spine is the highest of any structural lesions in all subgroups. Fatty lesions with a cut-off of ≥3 are primarily present in patients fulfilling the ASAS axSpA criteria, infrequent in possible axSpA patients and no-axSpA patients. Erosions and syndesmophytes in the spine are equally present in all groups. Fatty lesions are the only type of structural lesions that can potentially discriminate between patients with and without axSpA.

 

ASAS axSpA, n=126

Possible axSpA, n=116

No-axSpA, n=64

Imaging-arm

Clinical-arm, n=54

mNY+

n=26

mNY-

n=46

Fatty lesions ≥1

9 (34.6%)

18 (39.1%)

8 (14.8%)

19 (16.4%)

8 (12.5%)

Fatty lesions ≥2

5 (19.2%)

14 (30.4%)

6 (11.1%)

12 (10.3%)

7 (10.9%)

Fatty lesions ≥3

4 (15.4%)

11 (23.9%)

3 (5.6%)

10 (8.6%)

3 (4.7%)

Fatty lesions ≥4

4 (15.4%)

9 (19.6%)

2 (3.7%)

5 (4.3%)

2 (3.1%)

Fatty lesions ≥5

4 (15.4%)

7 (15.4%)

2 (3.7%)

4 (3.4%)

2 (3.1%)

Fatty lesions ≥6

3 (11.5%)

5 (10.9%)

2 (3.7%)

3 (2.6%)

2 (3.1%)

Fatty lesions ≥7

3 (11.5%)

4 (8.7%)

2 (3.7%)

3 (2.6%)

2 (3.1%)

Erosions ≥1

5 (19.2%)

11 (23.9%)

9 (16.7%)

20 (17.2%)

10 (15.6%)

Erosions ≥2

2 (7.7%)

6 (13.0%)

5 (9.3%)

10 (8.6%)

7 (10.9%)

Erosions ≥3

1 (3.8%)

2 (4.3%)

2 (3.7%)

3 (2.6%)

4 (6.3%)

Erosions ≥4

0

1 (2.2%)

0

3 (2.6%)

0

Erosions ≥5

0

0

0

1 (0.9%)

0

Syndesmophyt ≥1

5 (9.3%)

10 (21.7%)

1 (3.8%)

17 (14.7%)

7 (10.9%)

Syndesmophyt ≥2

1 (1.9%)

2 (4.3%)

0

8 (6.9%)

3 (4.7%)

Syndesmophyt ≥3

1 (1.9%)

0

0

2 (1.7%)

2 (3.1%)


Disclosure:

M. de Hooge,
None;

R. van den Berg,
None;

V. Navarro-Compán,
None;

M. Reijnierse,
None;

F. van Gaalen,
None;

K. Fagerli,
None;

M. C. Turina,
None;

M. van Oosterhout,
None;

R. Ramonda,
None;

T. Huizinga,
None;

D. van der Heijde,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-structural-lesions-seen-on-mri-spine-in-patients-with-possible-axial-spondyloarthritis-axspa-included-in-the-space-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology